{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T01:38:22Z","timestamp":1788053902741,"version":"build-2784847793"},"reference-count":37,"publisher":"American Chemical Society (ACS)","issue":"7","funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["HHSF223201010144A"],"award-info":[{"award-number":["HHSF223201010144A"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol. Pharmaceutics"],"published-print":{"date-parts":[[2015,7,6]]},"DOI":"10.1021\/acs.molpharmaceut.5b00154","type":"journal-article","created":{"date-parts":[[2015,5,22]],"date-time":"2015-05-22T13:52:13Z","timestamp":1432302733000},"page":"2436-2443","source":"Crossref","is-referenced-by-count":36,"title":["Biopharmaceutic Risk Assessment of Brand and Generic Lamotrigine Tablets"],"prefix":"10.1021","volume":"12","author":[{"given":"Soundarya","family":"Vaithianathan","sequence":"first","affiliation":[{"name":"Department\rof Pharmaceutical Sciences, University of Maryland, Baltimore, Maryland 21201, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddarth","family":"Raman","sequence":"additional","affiliation":[{"name":"Department\rof Pharmaceutical Sciences, University of Maryland, Baltimore, Maryland 21201, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlei","family":"Jiang","sequence":"additional","affiliation":[{"name":"Food and Drug Administration, Rockville, Maryland 20852, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tricia Y.","family":"Ting","sequence":"additional","affiliation":[{"name":"Department\rof Neurology, University of Maryland, Baltimore, Maryland 21201, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen A.","family":"Kane","sequence":"additional","affiliation":[{"name":"Department\rof Pharmaceutical Sciences, University of Maryland, Baltimore, Maryland 21201, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Polli","sequence":"additional","affiliation":[{"name":"Department\rof Pharmaceutical Sciences, University of Maryland, Baltimore, Maryland 21201, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2015,6,2]]},"reference":[{"issue":"10","key":"ref1\/cit1","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1111\/j.1528-1167.2007.01272.x","volume":"48","author":"Bialer M.","year":"2007","journal-title":"Epilepsia"},{"key":"ref2\/cit2","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.yebeh.2008.06.001","volume":"13","author":"Berg M. J.","year":"2008","journal-title":"Epilepsy Behavior"},{"key":"ref3\/cit3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1535-7511.2008.00261.x","volume":"8","author":"Privitera M. D.","year":"2008","journal-title":"Epilepsy Currents"},{"key":"ref4\/cit4","first-page":"A226","volume":"72","author":"Chuang K.","year":"2009","journal-title":"Neurology"},{"issue":"6","key":"ref5\/cit5","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1528-1167.2010.02573.x","volume":"51","author":"Bialer M.","year":"2010","journal-title":"Epilepsia"},{"key":"ref6\/cit6","unstructured":"Ligue Francaise Contre L\u2019Epilepsie (LFCE). Recommendation on the use of generic for the treatment of epilepsy.http:\/\/www.ilae-epilepsy.org(accessed January 29, 2015) ."},{"key":"ref7\/cit7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1528-1167.2006.00871.x","volume":"47","author":"Perucca E.","year":"2006","journal-title":"Epilepsia"},{"key":"ref8\/cit8","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1212\/01.wnl.0000259400.30539.cc","volume":"68","author":"Liow K.","year":"2007","journal-title":"Neurology"},{"key":"ref9\/cit9","unstructured":"American Epilepsy Society (AES). Position statement on the substitution of different formulations of antiepileptic drugs for the treatment of epilepsy.http:\/\/www.AESNET.org(accessed January 29, 2015) ."},{"issue":"3","key":"ref10\/cit10","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1016212804288","volume":"12","author":"Amidon G. L.","year":"1995","journal-title":"Pharm. Res."},{"key":"ref11\/cit11","unstructured":"Council of Experts.Lamotrigine Tablets;U.S. Pharmacopeia National Formulary, The United States Pharmacopeial Convention:Rockville, MD, 2011; pp3264\u20133266."},{"key":"ref12\/cit12","first-page":"221","volume":"270","author":"Yu L. X.","year":"2003","journal-title":"Int. J. Pharm."},{"key":"ref13\/cit13","unstructured":"Council of Experts.Disintegration;U.S. Pharmacopeia National Formulary, The United States Pharmacopeial Convention:Rockville, MD, 2011; pp276\u2013277."},{"key":"ref14\/cit14","unstructured":"Council of Experts.Loss on Drying;U.S. Pharmacopeia National Formulary, The United States Pharmacopeial Convention:Rockville, MD, 2011; pp304\u2013305."},{"issue":"10","key":"ref15\/cit15","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1002\/jps.10428","volume":"92","author":"Tolle-Sander S.","year":"2003","journal-title":"J. Pharm. Sci."},{"key":"ref16\/cit16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0378-5173(00)00334-3","volume":"200","author":"Lentz K. A.","year":"2000","journal-title":"Int. J. Pharm."},{"key":"ref17\/cit17","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1021\/mp300410n","volume":"10","author":"Incecayir T.","year":"2013","journal-title":"Mol. Pharmaceutics"},{"issue":"6","key":"ref18\/cit18","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/jps.20064","volume":"93","author":"Polli J. E.","year":"2004","journal-title":"J. Pharm. Sci."},{"key":"ref19\/cit19","unstructured":"Council of Experts.The Dissolution Procedure: Development and Validation;U.S. Pharmacopeia National Formulary, The United States Pharmacopeial Convention:Rockville, MD, 2011; pp624\u2013630."},{"key":"ref20\/cit20","unstructured":"SUPAC Expert Working Group of the Chemistry Manufacturing Controls Coordinating Committee (CMC CC) of the Center for Drug Evaluation and Research. Guidance for Industry Immediate Release SolidOral Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing,and Controls, In VitroDissolution Testing, andIn VivoBioequivalence Documentation.http:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/UCM070636.pdf, 1995, (accessed January 28, 2015) ."},{"issue":"2","key":"ref21\/cit21","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1208\/s12248-008-9027-6","volume":"10","author":"Polli J. E.","year":"2008","journal-title":"AAPS J."},{"key":"ref22\/cit22","unstructured":"GlaxoSmithKline Product Information.http:\/\/us.gsk.com\/products\/assets\/us_lamictal.pdf(accessed January 28, 2015) ."},{"key":"ref23\/cit23","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.addr.2012.09.019","volume":"64","author":"Lipinski C. A.","year":"2012","journal-title":"Adv. Drug Delivery Rev."},{"issue":"12","key":"ref24\/cit24","doi-asserted-by":"crossref","first-page":"4940","DOI":"10.1002\/jps.22217","volume":"99","author":"Butler J. M.","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"ref25\/cit25","unstructured":"CDER\/FDA. Guidance for Industry: Waiver ofin vivobioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System, 2000."},{"key":"ref26\/cit26","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ejps.2014.01.009","volume":"57","author":"Tsume Y.","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref27\/cit27","unstructured":"CDER\/FDA. Dissolution Methods.http:\/\/www.accessdata.fda.gov\/scripts\/cder\/dissolution\/index.cfm(accessed May 4, 2015) ."},{"key":"ref28\/cit28","unstructured":"CDER\/FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.http:\/\/www.accessdata.fda.gov\/scripts\/cder\/ob\/docs\/queryai.cfm(accessed May 4, 2015) ."},{"key":"ref29\/cit29","unstructured":"CDER\/FDA. Guidance on Lamotrigine.http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm209231.pdf(accessed May 4, 2015) ."},{"key":"ref30\/cit30","unstructured":"CDER\/FDA. Inactive Ingredient Search for Approved Products.http:\/\/www.accessdata.fda.gov\/scripts\/cder\/iig\/index.Cfm(accessed February 17, 2015) ."},{"issue":"6","key":"ref31\/cit31","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/dmd.106.009340","volume":"34","author":"Rowland A.","year":"2006","journal-title":"Drug Metab. Dispos."},{"issue":"8","key":"ref32\/cit32","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s11095-010-0170-2","volume":"27","author":"Tompkins L.","year":"2010","journal-title":"Pharm. Res."},{"key":"ref33\/cit33","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.eplepsyres.2014.08.004","volume":"108","author":"Ramey P.","year":"2014","journal-title":"Epilepsy Res."},{"key":"ref34\/cit34","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40261-013-0070-4","volume":"38","author":"Biton V.","year":"2013","journal-title":"Clin. Drug Invest."},{"key":"ref35\/cit35","unstructured":"GlaxoSmithKline Product Information.https:\/\/www.gsksource.com\/gskprm\/htdocs\/documents\/LAMICTAL-XR-PI-MG.PDF(accessed February 16, 2015) ."},{"key":"ref36\/cit36","unstructured":"CDER\/FDA. Clinical Pharmacology and Biopharmaceutics Reviews.http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/022115s000_ClinPharmR.pdf(accessed February 16, 2015) ."},{"issue":"3","key":"ref37\/cit37","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1528-1167.2007.01274.x","volume":"49","author":"Tompson D. J.","year":"2008","journal-title":"Epilepsia"}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.5b00154","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,22]],"date-time":"2023-04-22T05:24:47Z","timestamp":1682141087000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/doi\/10.1021\/acs.molpharmaceut.5b00154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,2]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7,6]]}},"alternative-id":["10.1021\/acs.molpharmaceut.5b00154"],"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5b00154","relation":{},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,2]]}}}